Nanwei Medical Technology Co., Ltd. was founded in 2000. The company is mainly engaged in the research, development, manufacturing and sales of minimally invasive medical devices. Adhering to the purpose of "serving clinical practice with technology and innovation", we are committed to providing high-quality products and services to medical institutions around the world, helping all over the world improve medical level, reduce patient pain, and reduce medical costs.

After nearly 20 years of innovative development, the company has gradually moved from a single non-vascular stent product to three major technology platforms, mainly from the domestic market to the domestic and international markets, and has become a high scientific research and innovation strength and core in the field of minimally invasive diagnosis and treatment. Product competitive advantage, industry leading company with rapid growth in performance.

The company has undertaken three national scientific research projects, owned 36 domestic and foreign invention patents, obtained 28 registration certificates for Class III medical devices and 45 registration certificates for Class II medical devices. It has successively won the honorary titles of National Torch Program Key High-tech Enterprise, Jiangsu Province Science and Technology Small and Medium-sized Enterprise, Jiangsu Province Key R&D Institution, Jiangsu Province Private Science and Technology Enterprise, etc.

The company's core products have competitive advantages. The company's main products include two main product series of endoscopic minimally invasive diagnostic and treatment devices and tumor ablation equipment. The company's newly developed endoscopic optical coherence tomography system (EOCT) has been obtained from the company's endoscopic minimally invasive diagnostic and treatment device product application. In the clinical diagnosis and treatment of digestive and respiratory diseases, it includes six sub-series of products, providing a systematic solution for endoscopic diagnosis and treatment. Among them, the technology that can carry 125I radiation therapy particle stent technology was rated as the world's first, and the main equipment for tumor ablation In order to perform precise microwave ablation of tumors, it has become one of the mainstream medical methods in the field of liver cancer treatment; EOCT is mainly used in conjunction with endoscopy and can be used for early cancer screening and surgical planning, and is expected to develop into the main means of "non-invasive optical biopsy". .

The domestic and international markets drive the development of the company. In the domestic market, the company's endoscopic diagnosis and treatment technology products have played a strong role in import substitution, effectively reducing the cost of endoscopic diagnosis and treatment and reducing the burden on patients. The company's products have been sold to more than 2,900 hospitals across the country, and the coverage rate of Grade A hospitals has reached more than 55%. In terms of foreign markets, the company has subsidiaries in the United States and Germany, and its products have passed the approval of the US FDA and the EU CE certification. The products are exported to more than 70 countries and regions including developed countries such as the United States, Germany, Canada, and Japan.

From 2016 to 2018, the company's sales revenue reached an average annual compound growth rate, with a growth rate far higher than the industry level. In order to maintain sustained growth, the company has strategically laid out its EOCT system with cutting-edge technical standards. It is the second product in the world to be approved by the US FDA. It is currently conducting clinical research in the Mayo Clinic, Stanford University Hospital Medical Center and other institutions in the United States. It is the company. An important growth point for future business development.

In the future, the company will continue to focus on the core capability of transforming medical innovation achievements, continue to grow bigger and stronger, and enter the new minimally invasive diagnosis and treatment field in a timely manner in the future, striving to make the company a global leader in the minimally invasive diagnosis and treatment field.